Cachexia has been recognised for a long time as an adverse effect of cancer. It is associated with reduced physical function, reduced tolerance to anticancer therapy, and reduced survival. Weight loss in patients with cancer is rarely recognised, assessed, or managed actively. Thus, cancer cachexia represents an important unmet need.
Cancer cachexia occurs in a third or more of all patients with cancer and has been estimated to be the direct cause of death in up to 20% of all cancer-related deaths. Colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) have relatively high incidences of cachexia, approximately 50%.
There is currently no widely approved therapeutic agent for treating cancer cachexia.
“There is currently no widely approved therapeutic agent for treating cancer cachexia.”
Fearon K, Arends J, Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013 Feb;10(2):90-9.
Vaughan V.C., Martin P., Lewandowski P.A. Cancer cachexia: impact, mechanisms and emerging treatments. J Cachex Sarcopenia Muscle 2013;2:95-109.
Aapro M, Arends J, Bozzetti F, Fearon K, Grunberg SM, Herrstedt J, et al. Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task Force. Ann Oncol 2014; 25: 1492–1499.
Cachexia therapy / Unmet / Medical need / Cancer / Drug development / Patient's lives / Innovation